Enzyme prodrug cancer therapy selectively targeted to tumor vasculature and methods of production and use thereof
Patent Number: US8986701
Executive Summary:
General Description:
Enzyme prodrug therapy is a two-step approach restrict the action of cytotoxic drugs to the site of the tumor only. First, a drug-activating compound is administered to the patient and is targeted specifically to the tumor cells. Second, a non-toxic prodrug is systemically administered. The prodrug is then converted to an active anticancer drug at the site of the tumor only, resulting in a high local concentration and reducing systemic side-effects.
Strengths:
Patent Status:
Inventor Bio: Roger G. Harrison
http://www.ou.edu/coe/cbme/people/faculty1/harrison.html
Executive Summary:
- Invention Type: Therapeutic
- Patent Status: Active
- Patent Link: https://patents.google.com/patent/US8986701/
- Research Institute: University of Oklahoma
- Disease Focus: Cancer
- Basis of Invention: Enzyme prodrug
- How it works: An annexin is operatively attached to an enzyme. The annexin will specifically bind tumor vasculature, resulting in the specific location of the enzyme to the tumor site. Next, selenomethionine prodrug is systemically administered to the patient. The prodrug will be converted by the enzyme into a cytotoxic anti-cancer drug at the site of the tumor only, resulting in high local concentrations
- Lead Challenge Inventor: Roger G. Harrison
- Development Stage: Pre-clinical
- Novelty:
- Targeting of tumor vasculature for tumor destruction
- Clinical Applications:
- Specific detection and destruction of tumor cells using photodynamic therapy
- Specific detection and destruction of tumor cells using photodynamic therapy
General Description:
Enzyme prodrug therapy is a two-step approach restrict the action of cytotoxic drugs to the site of the tumor only. First, a drug-activating compound is administered to the patient and is targeted specifically to the tumor cells. Second, a non-toxic prodrug is systemically administered. The prodrug is then converted to an active anticancer drug at the site of the tumor only, resulting in a high local concentration and reducing systemic side-effects.
Strengths:
- High local concentration of drug resulting in less systemic side-effects
Patent Status:
- Filing date: 2009-10-19
Inventor Bio: Roger G. Harrison
http://www.ou.edu/coe/cbme/people/faculty1/harrison.html
